Stephen Greene, MD
Advanced Heart Failure and Transplant Cardiology · Durham, NCNPI 1003170861
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $404,889 of the $581,784 with a category attached, or 69.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 13.4%. Reporting peaked in 2024 at $225,999 and has fallen 64.9% since, to $79,271 in 2025. Among advanced heart failure and transplant cardiology clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 300 payments — averaging $1939.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$78K
- Lexicon Pharmaceuticals, Inc.$62K
- Novo Nordisk AS$54K
- Amgen$46K
- Vifor (international) Ltd.$36K
- Novo Nordisk$35K
- plus $272K from 23 others
Across 11 payments — averaging $14,862 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$113K
- Amgen$42K
- Bayer$6K
- Sanofi-aventis U.S. LLC$2K
What the payments were for
- Consulting fees$404,88970%
- Speaking & faculty fees$99,45217%
- Travel & lodging$71,69312%
- Food & beverage$5,4971%
- Education$2530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 58 | $77,991 |
| Lexicon Pharmaceuticals, Inc. | 26 | $61,596 |
| Novo Nordisk AS | 13 | $53,869 |
| Amgen | 22 | $46,107 |
| Vifor (international) Ltd. | 14 | $35,708 |
| Novo Nordisk | 24 | $34,836 |
| Roche Diagnostics International Ltd | 10 | $34,664 |
| AstraZeneca | 23 | $34,527 |
| E.r. Squibb & Sons, L.L.C. | 11 | $26,932 |
| Eli Lilly | 12 | $23,307 |
| Roche Diagnostics Corporation | 10 | $18,343 |
| Corcept Therapeutics | 9 | $13,664 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $13,500 |
| Lilly USA, LLC | 6 | $12,600 |
| Astrazeneca UK Limited | 10 | $10,746 |
| Boehringer Ingelheim | 15 | $10,517 |
| Bayer | 3 | $10,220 |
| Sanofi-aventis U.S. LLC | 2 | $9,906 |
| Mylan Inc. | 3 | $8,732 |
| Boehringer Ingelheim International GmbH | 1 | $8,525 |
| Recordati_rare_diseases_inc. | 7 | $8,491 |
| Vifor Fresenius Medical Care Renal Pharma Ltd. | 1 | $8,407 |
| Idorsia Pharmaceuticals US Inc | 2 | $7,254 |
| Scpharmaceuticals Inc. | 2 | $7,200 |
| Medtronic | 3 | $1,231 |
| Novartis | 6 | $1,192 |
| Urovant Sciences Inc | 1 | $820 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $805 |
| Boston Scientific | 1 | $97 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$581,784 in reported general payments places this provider in the 95th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 145 | $147,378 |
| EntrestoSacubitril/Valsartan | 114 | $124,819 |
| OzempicSemaglutide | 42 | $40,208 |
| EliquisApixaban | 24 | $25,798 |
| FarxigaDapagliflozin Propanediol | 16 | $16,698 |
| XareltoRivaroxaban | 11 | $11,353 |
| Torsemide | 37 | $1,147 |
| Metoprolol Succinate | 73 | $1,098 |
| Atorvastatin Calcium | 70 | $707 |
| Valsartan | 13 | $615 |
| Spironolactone | 95 | $588 |
| Carvedilol | 54 | $446 |
| Rosuvastatin Calcium | 14 | $300 |
| Potassium Chloride | 11 | $282 |
| Amlodipine Besylate | 17 | $199 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $10,517 | $147,378145 claims |
| NovartisEntresto | $1,192 | $124,819114 claims |
| Novo NordiskOzempic | $34,836 | $40,20842 claims |
| AstraZenecaFarxiga | $34,527 | $16,69816 claims |
| Mylan Inc.Atorvastatin Calcium | $8,732 | $70770 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
Other advanced heart failure and transplant cardiology in Durham
- Merna HussienDurham$18K
- Richa AgarwalDurham$13K
- Fawaz Abdulaziz M AleneziDurham$2K
- Daniel BensimhonGreensboro$2.1M
- John RommelWilmington$263K
- Stephen ZouzoulasConcord$244K
- Hassan AlhosainiWinston Salem$195K
- Vinay ThohanAsheville$164K
- Kishan ParikhRaleigh$158K
- Emil MissovGreenville$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.